Tango Therapeutics, Inc. (TNGX) — Operating Cash Flow
| Fiscal Year | Operating Cash Flow | Change YoY |
|---|---|---|
| 2025 | -$138.89M | -5.6% |
| 2024 | -$131.50M | -11.5% |
| 2023 | -$117.98M | -8.2% |
| 2022 | -$109.08M | -83.2% |
| 2021 | -$59.53M | -184.9% |
| 2020 | $70.07M | — |
| Fiscal Year | Operating Cash Flow | Change YoY |
|---|---|---|
| 2025 | -$138.89M | -5.6% |
| 2024 | -$131.50M | -11.5% |
| 2023 | -$117.98M | -8.2% |
| 2022 | -$109.08M | -83.2% |
| 2021 | -$59.53M | -184.9% |
| 2020 | $70.07M | — |